PARP1 and neoplasm: BMN 673, an inhibitor of PARP catalytic activity, has exhibited selective anti-tumor activity at much lower concentrations (IC50 = 0.57 nM) than the earlier generation of PARP inhibitors, including olaparib, rucaparib, and veliparib.